Safety Guide for the Use of Doxorubicin, Epirubicin, and Pirarubicin: Essential Reading for Toxicity Prevention and Control

I. Core Commonalities of the Three Drugs: Mechanism of Action and Basic Characteristics

Doxorubicin, epirubicin, and pirarubicin are all anthracycline antitumor antibiotics with highly consistent core mechanisms of action. They exert their antitumor effects by intercalating into the double-stranded DNA of tumor cells, thereby interfering with DNA replication and transcription, inhibiting tumor cell proliferation and division. In addition, they inhibit the activity of topoisomerase II and induce apoptosis of tumor cells, ultimately achieving tumor cell killing and control of tumor progression.

All three are cell cycle–nonspecific agents and are cytotoxic to tumor cells at different phases of the cell cycle. Clinically, they are mainly used in the treatment of various malignant tumors, including hematologic malignancies and solid tumors. However, due to minor differences in chemical structure (such as differences in substituent groups), they vary in lipophilicity, tissue penetration, and metabolic rate, which in turn affect their clinical efficacy, toxicity profiles, and appropriate clinical applications.

II. Detailed Analysis of the Three Drugs: Indications, Usage, and Characteristics

(1) Doxorubicin: A Classic Broad-Spectrum Agent with Strong Antitumor Activity

Doxorubicin, also known as Adriamycin, is one of the most classic and widely used anthracyclines. Since its introduction, it has become a first-line agent for the treatment of various malignancies due to its powerful broad-spectrum antitumor activity.

1.  Core Indications:

Primarily used for the treatment of hematologic malignancies such as acute lymphoblastic leukemia, acute granulocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. It is also used in solid tumors, including breast cancer, lung cancer, gastric cancer, liver cancer, bladder cancer, ovarian cancer, and soft tissue sarcomas, with particularly notable efficacy in breast cancer and lymphomas.

2.  Dosage and Administration:

Most commonly administered via intravenous injection. The specific dose should be adjusted based on patient body weight, tumor type, treatment regimen, and hepatic and renal function. In monotherapy, the typical adult dose is 40–60 mg/m² per administration, with one cycle every 3 weeks. In combination chemotherapy, the dose should be appropriately reduced to avoid additive toxicities.

3.  Key Characteristics:

Broad antitumor spectrum and strong activity, making it a commonly used agent in combination chemotherapy. However, its toxicities are relatively pronounced, particularly cardiotoxicity and bone marrow suppression. Strict monitoring is required with long-term or high-dose use.

(2) Epirubicin: Lower Toxicity and Better Tolerability

Epirubicin is a stereoisomer of doxorubicin. Through chemical structural modification of doxorubicin, its toxicity has been reduced while retaining antitumor activity, resulting in improved clinical safety and better tolerability compared with doxorubicin.

1.  Core Indications:

Similar to those of doxorubicin, epirubicin is used in the treatment of acute leukemia, lymphoma, breast cancer, lung cancer, gastric cancer, ovarian cancer, cervical cancer, and colorectal cancer. It is particularly widely used in adjuvant and palliative treatment of breast and lung cancer and is especially suitable for patients who are intolerant to doxorubicin.

2.  Dosage and Administration:

Mainly administered intravenously, with doses adjusted according to individual patient conditions. In monotherapy, the adult dose is 60–90 mg/m² per administration every 3 weeks. In combination chemotherapy, the dose may be reduced to 50–75 mg/m², as directed by the physician.

3.  Key Characteristics:

Compared with doxorubicin, epirubicin has significantly reduced cardiotoxicity and bone marrow suppression, and gastrointestinal reactions (such as nausea and vomiting) are milder, resulting in better patient tolerability. However, its antitumor activity is slightly lower than that of doxorubicin. Clinically, it is often used as a substitute for doxorubicin in patients requiring long-term chemotherapy or those with weaker physical conditions.

(3) Pirarubicin: High Lipophilicity with Prominent Local Efficacy

Pirarubicin is a new-generation anthracycline antitumor drug with a chemical structure different from doxorubicin and epirubicin. Its higher lipophilicity facilitates penetration through tumor cell membranes and accumulation within tumor tissues, resulting in more pronounced local antitumor effects and further reduced systemic toxicity.

1.  Core Indications:

In addition to treating common malignancies such as acute leukemia, lymphoma, breast cancer, lung cancer, and gastric cancer, pirarubicin is particularly effective in urinary and reproductive system tumors, including bladder cancer, cervical cancer, and endometrial cancer. Furthermore, it can be used for local perfusion therapy (e.g., intravesical instillation for bladder cancer), directly targeting tumor sites to enhance therapeutic efficacy.

2.  Dosage and Administration:

Flexible routes of administration include intravenous injection, intra-arterial injection, and intravesical instillation. In intravenous monotherapy, the adult dose is 40–60 mg/m² per administration every 3 weeks. For intravesical instillation, the dose is 30–50 mg per administration once weekly for 4–8 consecutive treatments per cycle, with dosing adjusted according to treatment site and disease condition.

3.  Key Characteristics:

High lipophilicity, strong tumor tissue penetration, high local concentration, and prominent efficacy in localized treatment. Systemic toxicities (cardiotoxicity and bone marrow suppression) are lower than those of doxorubicin and epirubicin, with mild gastrointestinal reactions and the best overall tolerability. However, its cost is relatively higher, and clinical use should consider both patient economic status and disease requirements.

III. Summary of Key Differences Among the Three Drugs

To facilitate rapid differentiation among doxorubicin, epirubicin, and pirarubicin, the following table summarizes their core distinctions:

IV. Clinical Precautions for Use (Key Reminders)

Doxorubicin, epirubicin, and pirarubicin are all cytotoxic agents and must be used strictly in accordance with medical advice. The following points should be carefully considered to avoid adverse reactions:

1.  Monitoring of Cardiotoxicity:

All three drugs may cause cardiotoxicity, with the highest risk associated with doxorubicin and lower risks with epirubicin and pirarubicin. Electrocardiography and echocardiography should be performed before treatment to assess cardiac function, with regular monitoring during therapy. Concomitant use with other cardiotoxic drugs should be avoided, and cardioprotective agents (e.g., dexrazoxane) may be used when necessary.

2.  Management of Bone Marrow Suppression:

All three agents suppress bone marrow hematopoiesis, leading to leukopenia and thrombocytopenia, increasing the risk of infection and bleeding. Routine blood counts should be monitored regularly after treatment. If bone marrow suppression occurs, appropriate supportive measures such as leukocyte- or platelet-stimulating agents should be administered, along with infection prevention and injury avoidance.

3.  Management of Local Reactions:

During intravenous administration, drug extravasation may cause local redness, pain, or necrosis. Proper needle placement within the vessel should be ensured to prevent extravasation. If extravasation occurs, administration should be stopped immediately and appropriate measures such as cold compresses and antidote injections should be initiated. After intravesical instillation of pirarubicin, patients should be advised to increase fluid intake to promote drug excretion and reduce bladder irritation.

4.  Contraindications in Special Populations:

Contraindicated in pregnant and lactating women. Dose reduction is required in patients with hepatic or renal impairment, and use is contraindicated in severe hepatic or renal dysfunction. Caution is required in patients with a history of cardiac disease, particularly when using doxorubicin.

5.  Administration Standards:

Strict adherence to prescribed doses and treatment cycles is required. Unauthorized dose escalation or prolonged treatment duration should be avoided to prevent drug accumulation and increased toxicity.

V. Conclusion

As core anthracycline antitumor agents, doxorubicin, epirubicin, and pirarubicin each have distinct advantages. Doxorubicin offers broad-spectrum efficacy and low cost and remains a first-line foundational agent, though its toxicity is relatively pronounced. Epirubicin has lower toxicity and better tolerability, making it suitable as an alternative to doxorubicin in patients with weaker physical conditions or those requiring long-term chemotherapy. Pirarubicin, with its high lipophilicity, prominent local efficacy, and lowest toxicity, is particularly well suited for localized treatment of urinary and reproductive system tumors, albeit at a higher cost.

Clinical use should integrate tumor type, disease stage, patient physical condition, and economic factors, with rational selection of drugs and treatment regimens under professional medical guidance to maximize antitumor efficacy while minimizing adverse reactions, thereby supporting optimal patient recovery.

At DengyuePharma, we believe that everyone, regardless of location, should have access to high-quality healthcare services. Our mission is to enable people worldwide to obtain Chinese innovative medicines safely, legally, and affordably. Wherever you are, we are committed to serving you and meeting your trusted healthcare needs. Health knows no borders—with HKDengyueMed, neither do your medicines.